首页> 外文期刊>European journal of medical research. >Clinical efficacy of radical nephrectomy versus nephron-sparing surgery on localized renal cell carcinoma
【24h】

Clinical efficacy of radical nephrectomy versus nephron-sparing surgery on localized renal cell carcinoma

机译:根治性肾切除术的临床疗效与肾脏味道术后肾细胞癌的临床疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The aim of the present study was to compare the clinical efficacy of radical nephrectomy (RN) with nephron-sparing surgery (NSS) in treating patients with localized renal cell carcinoma (RCC). Methods: The literature search was performed in PubMed, MEDLINE Springer, Elsevier Science Direct, Cochrane Library, and Google Scholar up to December 2012. The software Review Manager 5.1 and the STATA software package v.11.0 were used for analyses. The odds ratios (ORs) and its 95% confidence interval (95% CI) were calculated for comparison. Subgroup analyses were performed based on the tumor size of RCC. Results: In total, 10 studies with 10,174 RCC patients (7,050 treated with RN and 3,124 treated with NSS) were selected. The pooled estimate (OR = 1.58, 95% CI = 1.15-2.15, P = 0.004) showed a significantly lower rate of cancer-specific deaths in the patients treated with NSS compared to RN. However, no statistically significant differences were found in the rate of tumor recurrence (OR = 0.84, 95% CI = 0.67-1.06, P = 0.14) and complications (OR = 0.91, 95% CI = 0.51-1.63, P = 0.74) between the patients treated with NSS and RN. In addition, all the subgroup analyses presented consistent results with the overall analyses. Conclusions: NSS had no significantly different from RN in tumor recurrence and complications for localized RCC. However, the significantly lower rate of cancer-specific deaths supported the use of NSS not only for RCC with tumor size >4.0 cm but also for tumor sizes <4.0 cm compared with RN.
机译:背景:本研究的目的是比较自由基肾切除术(RN)与肾儿保留手术(NSS)治疗局部肾细胞癌(RCC)患者的临床疗效。方法:文献搜索是在PubMed,Medline Springer,Elsevier Science Direct,Cochrane图书馆和Google Scholar的比赛中进行的,距离2012年12月。5.1和Stata软件包V.11.0用于分析。计算差距(或)及其95%置信区间(95%CI)进行比较。基于RCC的肿瘤大小进行亚组分析。结果:总共有10项研究,10174名RCC患者(用NSS处理的RN和3,124次处理7,050次)。与RN相比,汇总估计(或= 1.58,95%CI = 1.15-2.15,P = 0.004)显示,用NSS治疗的患者患者的癌症特异性死亡率显着降低。但是,在肿瘤复发率(或= 0.84,95%CI = 0.67-1.06,P = 0.14)和并发症中没有发现统计学上显着的差异(或= 0.84,95%CI = 0.14)(或= 0.91,95%CI = 0.51-1.63,P = 0.74)在用NSS和RN治疗的患者之间。此外,所有子组分析都会通过整体分析呈现一致的结果。结论:NSS与肿瘤复发和局部RCC并发症的RN没有显着差异。然而,癌症特异性死亡率的显着较低率不仅适用于肿瘤大小> 4.0cm的rCC,而且对于肿瘤尺寸与RN相比,肿瘤尺寸<4.0cm。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号